Analysts Set QuidelOrtho Corporation (NASDAQ:QDEL) PT at $13.62

QuidelOrtho Corporation (NASDAQ:QDEL) has been given an average recommendation of “Reduce” by the six ratings firms that are currently covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a sell recommendation and three have issued a hold recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $13.6250.

A number of brokerages recently issued reports on QDEL. Citigroup lifted their target price on QuidelOrtho from $13.00 to $18.00 and gave the stock a “neutral” rating in a report on Wednesday, July 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of QuidelOrtho in a research note on Friday, July 17th. JPMorgan Chase & Co. boosted their price objective on QuidelOrtho from $11.00 to $12.00 and gave the stock an “underweight” rating in a report on Wednesday, July 1st. Jefferies Financial Group reiterated a “hold” rating on shares of QuidelOrtho in a report on Monday, June 29th. Finally, Wall Street Zen raised shares of QuidelOrtho from a “sell” rating to a “hold” rating in a research report on Sunday, June 28th.

QuidelOrtho Stock Down 4.2%

QDEL stock opened at $10.62 on Thursday. The firm has a market cap of $728.21 million, a PE ratio of -0.69 and a beta of 0.68. QuidelOrtho has a 12 month low of $9.92 and a 12 month high of $35.58. The company has a debt-to-equity ratio of 1.43, a current ratio of 1.39 and a quick ratio of 0.76. The firm has a 50 day simple moving average of $14.85 and a 200 day simple moving average of $14.81.

QuidelOrtho (NASDAQ:QDEL) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.18. QuidelOrtho had a negative net margin of 39.20% and a positive return on equity of 4.88%. The firm had revenue of $630.90 million for the quarter, compared to analyst estimates of $618.72 million. During the same quarter in the previous year, the business posted $0.12 earnings per share. The firm’s quarterly revenue was up 2.8% compared to the same quarter last year. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. Equities research analysts forecast that QuidelOrtho will post 0.75 earnings per share for the current fiscal year.

Hedge Funds Weigh In On QuidelOrtho

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in QDEL. Integrated Wealth Concepts LLC purchased a new stake in shares of QuidelOrtho in the second quarter valued at $53,000. IFP Advisors Inc grew its holdings in shares of QuidelOrtho by 14,166.7% during the second quarter. IFP Advisors Inc now owns 2,568 shares of the company’s stock valued at $45,000 after buying an additional 2,550 shares in the last quarter. Squarepoint Ops LLC purchased a new position in shares of QuidelOrtho during the second quarter valued at $1,493,000. Allworth Financial LP raised its position in QuidelOrtho by 161.3% during the second quarter. Allworth Financial LP now owns 3,209 shares of the company’s stock valued at $56,000 after buying an additional 1,981 shares during the period. Finally, Corient Private Wealth LP acquired a new position in QuidelOrtho during the second quarter valued at $363,000. Institutional investors and hedge funds own 99.00% of the company’s stock.

QuidelOrtho Company Profile

QuidelOrtho Corporation (NASDAQ:QDEL) develops, manufactures and distributes diagnostic products and solutions used to detect and monitor disease. The company serves hospitals, clinical laboratories, physician offices, retail clinics, blood banks and other healthcare providers worldwide.

Its portfolio includes point-of-care and molecular testing systems, immunoassays, clinical chemistry and immunodiagnostic platforms, and transfusion medicine products. Key product lines include the Sofia and QuickVue systems from Quidel and the VITROS, ORTHO Vision and ORTHO Workstation platforms from Ortho Clinical Diagnostics.